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Central nervous system (CNS) disorders have a social and economic burden on
modern societies, and the development of effective therapies is urgently required. Gene
editing may prevent or cure a disease by inducing genetic changes at endogenous
loci. Genome editing includes not only the insertion, deletion or replacement of
nucleotides, but also the modulation of gene expression and epigenetic editing.
Emerging technologies based on ZFs, TALEs, and CRISPR/Cas systems have extended
the boundaries of genome manipulation and promoted genome editing approaches
to the level of promising strategies for counteracting genetic diseases. The parallel
development of efficient delivery systems has also increased our access to the CNS. In
this review, we describe the various tools available for genome editing and summarize
in vivo preclinical studies of CNS genome editing, whilst considering current limitations
and alternative approaches to overcome some bottlenecks.
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INTRODUCTION
Neurological disorders are the principal cause of disability and the second leading cause of death
worldwide (Feigin et al., 2019). Central nervous system (CNS) diseases include diverse infections
(meningitis and encephalitis), vascular disorders (stroke and other hemorrhages), structural (brain
or spinal injury), functional (epilepsy and migraines) and neurodegenerative (Alzheimer’s and
Parkinson’s disease) conditions. With steady increases in the size and age of the world population,
the prevalence of these diseases is likely to increase, and they have thus become a priority area of
research. The age-standardized frequencies of neurological diseases have declined, but the number
of people affected worldwide has continued to increase. The continual aging of the population is,
thus, outstripping our ability to counteract these disorders (Feigin et al., 2019).
The development of therapeutic strategies for CNS disorders is challenging, given the
considerable diversity of cells involved, the extreme complexity of the neural circuits and
associated functions, poor tissue regeneration and our incomplete understanding of the underlying
pathological processes. Pharmacological efficacy depends on our ability to take all of these factors
into account. For some disorders, such as traumatic and neurodegenerative conditions, the timing
of treatment may also be important, with therapeutic success decreasing as neurodegeneration
progresses. Moreover, the blood–brain barrier (BBB) limits the diffusion of most molecules
delivered by conventional methods. Consequently, the doses of drugs delivered systemically often
have to be increased to ensure that therapeutic concentrations are reached in the CNS, which may
lead to toxicity.
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As a result of these challenges, approval rates are much lower
for CNS-targeting drugs than for drugs targeting other parts of
the body (Kesselheim et al., 2015; Gribkoff and Kaczmarek, 2017).
This has led to a revision of CNS drug development guidelines
and to the implementation of innovative and efficient therapeutic
models. One particular treatment strategy, gene therapy, has
progressed remarkably over the last 15 years. It involves the
introduction of recombinant nucleic acids into the patient’s cells,
to fight or prevent a disease (Klug et al., 2012). Two different
therapeutic approaches can be used: ex vivo and in vivo. Ex vivo
gene therapy entails: (1) the collection of cells from the patient,
(2) the culture and modification of these cells in vitro and (3) the
transplantation of the modified cells back into the recipient. The
in vivo approach involves modification of cells directly in the
individual. One of the major advantages of gene therapy is that
it can be used to modify most biological pathways through the
targeting of the underlying genes. It can halt or reverse disease
progression by targeting the underlying pathogenic processes,
whereas conventional medicine often focuses on symptom relief.
In addition, stable transgene expression or permanent genome
modification may make it possible to treat disorders in a
single administration.
The most straightforward application of gene therapy is the
treatment of monogenic disorders. A classical approach to the
treatment of diseases caused by loss-of-function (LOF) mutations
is based on the replacement of the defective gene with the
wild-type (WT) cDNA. The treatment of familial lipoprotein
lipase deficiency (LPLD) with Glybera (a rAAV1 encoding
the lipoprotein lipase variant LPLS447X; Ylä-Herttuala, 2012),
a rare form of inherited blindness with Luxturna (a rAAV2
encoding a normal copy of the retinal pigment epithelium-
specific 65 kDa protein; Russell et al., 2017), and spinal
muscular atrophy (SMA) with Zolgensma (a rAAV9 encoding
the survival motor neuron 1 protein; Hoy, 2019) provide
examples of approved products. The treatment of autosomal
dominant disorders caused by gain-of-function (GOF) mutations
generally involves decreasing the levels of mutant mRNA by
RNA interference (RNAi) or with antisense oligonucleotides
(ASO). An example is provided by mipomersen, an ASO
targeting the apolipoprotein B mRNA, which can be used to treat
homozygous familial hypercholesterolemia (Hair et al., 2013).
Gene therapy products have been also developed to combat genes
in which the pathological mutation alters transcript splicing.
Examples include eteplirsen for Duchenne muscular dystrophy
(DMD) (Syed, 2016) and nusinersen (Spinraza R©) for SMA (Hoy,
2017). These products deliver nucleic acids targeting the mutant
primary transcripts, and modify the splicing of these transcripts
into non-pathogenic isoforms. Finally, gene-based therapeutic
approaches have also been successfully used for the treatment
of polygenic diseases, such as cancer and infectious diseases
(Shahryari et al., 2019). In such cases, the strategies developed
target one of the identified pathogenic genes (LOF or GOF) or
deliver transgenes encoding factors with protective functions.
Gene replacement approaches have been successfully applied
to some disorders, but (1) the size of the transgene may be limited
by the delivery system, (2) this approach is usually restricted to
the expression of a single gene isoform and (3) the lack of a
transgene chromatin signature often results in non-physiological
levels of expression (Khabou et al., 2018). Conversely, gene
silencing with RNAi/ASO (1) does not completely knockout
the pathological gene, and a total knockout may be essential
for highly damaging genes, (2) its therapeutic efficacy depend
on the turnover of the targeted transcript and (3) may require
continuous drug administration to maintain the therapeutic
benefit (Sledz and Williams, 2005).
Genome editing has emerged as a complementary gene
therapy strategy. It operates at native DNA loci, and can
be used for the complete inactivation of a toxic gene, gene
repair or regulation of an endogenous gene (Doudna, 2020).
Genome editing tools have been available for 30 years, but their
limited efficacy, complex production and the lack of efficient
delivery vehicles have delayed their clinical application. Over
the last decade, more sophisticated and precise editing tools
have rendered genome engineering not only promising for gene-
based therapeutic approaches, but also useful as a technique for
basic biology, genetic diagnosis and drug discovery purposes
(Doudna, 2020; Li et al., 2020; Sandoval et al., 2020; Wertz
et al., 2020). Indeed, therapeutic genome editing is no longer a
concept for the distant future, and several ex vivo and in vivo
therapeutic approaches are currently undergoing clinical testing
for the treatment of various diseases (Schacker and Seimetz, 2019;
Li et al., 2020). In this review, we describe the various genome
editing tools available and summarize some of the preclinical
studies of in vivo CNS genome editing published to date, while
discussing current limitations and alternative approaches to
overcome some of the bottlenecks.
DNA-BINDING PLATFORMS
Editing platforms have two key features essential for the
specific and efficient modification of target sequences within
the genome: (1) a DNA-binding domain recognizing a unique
target sequence and (2) an effector element for inducing
precise genetic/epigenetic modifications. The genome editing
tools currently available are based on three major DNA-binding
platforms: zinc fingers (ZFs), transcription-activator like effectors
(TALEs), and clustered regularly interspaced short palindromic
repeats (CRISPR/Cas).
Zinc fingers are eukaryotic DNA-binding domains consisting
of two anti-parallel β-sheets and one α-helix, the residue
composition of which specifies binding to particular triplets
(Miller et al., 1985; Pavletich and Pabo, 1991). Merging six ZFs,
is sufficient to create larger DNA-recognition domains targeting
unique sequences (18 base pairs) in eukaryotic genomes (Urnov
et al., 2010). The construction of extensive libraries of ZFs has
made it possible to engineer zinc finger proteins (ZFPs) targeting
almost any sequence desired.
Transcription-activator like effectors were first discovered in
Xanthomonas, a plant-pathogenic bacterium (Bonas et al., 1989;
Boch and Bonas, 2010). These proteins bind the DNA via a
central region containing an array of 33- to 35-amino acid motifs.
The amino-acid sequences of arrays are similar except for two
positions, conferring nucleotide-binding specificity. Unlike ZFs,
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in which each domain recognizes a specific trinucleotide, each
TALE array recognizes a single nucleotide.
CRISPR/Cas are the most recently developed tools for genome
engineering. They are based on an RNA-guided nuclease, the
DNA-binding properties of which are easily modulated by a
short RNA sequence (Fineran and Charpentier, 2012; Wiedenheft
et al., 2012). They are involved in bacterial adaptable immunity
and can be grouped into two main classes according to the
complexity of the nuclease effector (Makarova et al., 2015, 2020).
Class 1 systems (types I, III, and IV) involve a large complex
of several effector proteins, whereas class 2 systems (types II,
V, and VI) use a single Cas protein to mediate the recognition
and cleavage of foreign nucleic acids. Class 2 systems are the
most widely used for genome editing, because of their simple
structure. Type II and type V CRISPR/Cas ribonucleoprotein
complexes recognize specific DNA sequences through RNA-
DNA base pairing. Cas binding and interference are determined
by the spacer sequence (∼20 bp) of the single guide RNA
(sgRNA), and the protospacer adjacent motif (PAM) on the
target DNA. The spacer is complementary to the target sequence
and the PAM is a short DNA motif immediately adjacent to
the target region. Cas9 (type II) and Cas12a (type V) have
been extensively explored for genome editing (Jinek et al.,
2012; Cong et al., 2013; Mali et al., 2013; Zetsche et al.,
2015). Cas9 requires a 3′ PAM to the target sequence, whereas
Cas12a recognizes a 5′ PAM on the non-targeted strand. Cas9
induces PAM-proximal blunt double-strand breaks (DSBs) and
Cas12a creates PAM-distal staggered DSBs. PAM requirements
make it impossible for a single CRISPR/Cas system to target
all genomic sequences, but the use of different Cas9 and
Cas12a orthologs with different PAM specifications has greatly
expanded targeting capabilities (Cebrian-Serrano and Davies,
2017). In addition, Cas9 proteins have been engineered to
accept different and less restrictive PAMs, although sometimes
compromising the specificity (Hu et al., 2018; Walton et al.,
2020). By contrast, other groups have restricted Cas9 binding
parameters to increase specificity, which however reduce the
editing efficiency (Kleinstiver et al., 2016; Kocak et al., 2019). The
major advantage of CRISPR/Cas-based tools over ZFs and TALEs
for genome editing is the ease of engineering of the DNA-binding
domain to recognize unique sequences. The DNA-binding
specificity of ZFs and TALEs is dependent on protein-DNA
interactions and the targeting of particular sequences therefore
requires protein design. The genome-targeting specificity of
CRISPR/Cas is provided by the sgRNAs, which are simpler and
less expensive to design.
FUSING DNA-BINDING DOMAINS TO
EFFECTOR DOMAINS: GENOME
EDITING APPROACHES
Genome editing can be grouped into four approaches, depending
on the effector domains used (Table 1). The DNA sequence can
be permanently altered by gene editing or base editing, whereas a
transient or stable modification of DNA function/expression can
be achieved with gene regulation or epigenetic editing.
Gene Editing
The effector domain of gene editing platforms is a nuclease that
induces DSBs at the target DNA sequence (Doudna, 2020; Li et al.,
2020). Cas proteins possess intrinsic nuclease activity, whereas
ZF nucleases (ZFNs) and TALE nucleases (TALENs) have been
engineered by fusing the catalytic domain of the FokI nuclease
to ZFs and TALEs, respectively (Figure 1A). FokI is a bipartite
endonuclease that must dimerize to cleave the target sequence
(Vanamee et al., 2001). ZFNs and TALENs therefore have
two fused FokI domains binding opposite strands of adjacent
sequences in reverse orientations, to promote FokI dimerization
and genome restriction (Figure 1A). Spatial orientation and
module spacing requirements decrease the probability of off-
target cutting events. Site-specific DNA cleavage activates cellular
DNA repair pathways, which then delete, insert or replace
nucleotide sequences (Yeh et al., 2019). The two main DNA
repair pathways for DSBs are the non-homologous end-joining
(NHEJ) and homology-directed repair (HDR) pathways. NHEJ
is error-prone, often introducing small insertions or deletions
(indels), whereas HDR uses homologous sequences as a template,
to ensure the correct repair of damaged DNA (Figure 1B).
The NHEJ pathway is frequently used to inactivate toxic genes
(Figure 1B). The introduction of indels at the 5′ end of the target
gene results in frameshift mutations, generating premature stop
codons. Other applications include the disruption of aberrant
splicing sites or the deletion of large fragments of DNA through
the creation of two DSBs in the same chromosome (Figure 1B).
By contrast, the accuracy of the HDR pathway allows precise
nucleotide insertions, deletions or substitutions at the target
site (Figure 1B). This is achieved by using double- or single-
stranded DNA templates containing the intended modification,
flanked by homologous sequences. HDR can, thus, be used to
correct both GOF and LOF mutations, for gene repair. HDR
can also be exploited as an alternative approach to classical gene
replacement, to improve control over the copy number of the
gene of interest and to prevent insertional mutagenesis due to
the random integration of viral vectors. HDR-mediated gene
replacement involves the site-specific insertion of full transgenes
(cDNA) at “safe harbor” locations, defined as sites within the
genome at which the addition of sequences does not interfere
with the neighboring genes and results in safe robust transgene
expression (Figure 1B).
HDR-mediated gene editing is a promising approach for
therapeutic applications, but it is generally less efficient than
NHEJ and mostly restricted to the G2 and S phases of the
cell cycle (Yeh et al., 2019). This imposes additional challenges
for the application of HDR-based editing to post-mitotic cells
and, therefore, to CNS disorders. Nishiyama and colleagues
reported a high efficiency of HDR in the mouse brain (Nishiyama
et al., 2017), but most groups have struggled to achieve such
success with this approach. Several groups have proposed
NHEJ-like strategies to overcome this limitation through
precise gene editing in non-replicative cells by microhomology-
mediated end-joining (MMEJ) (Yao et al., 2017b), homology-
independent targeted integration (HITI) (Suzuki et al., 2016), and
microhomology-dependent targeted integration (MITI) (Li et al.,
2019). Other groups have explored HDR-like mechanisms, such
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TABLE 1 | Comparison of the different genome editing approaches.
Editing approaches Advantages Disadvantages
Gene editing Efficient
Permanent
All possible modifications: insertion, deletion and substitution
Off-target cleavage
Chromosomal instability
Target sequence restriction (PAM for CRISPR; 5’-T for TALENs)
NHEJ is heterogeneous
HDR is inefficient (especially in post-mitotic cells)
Base editing Permanent
No need to induce DSBs
Few or no indels
Off-target at both DNA and RNA level
Bystander base editing
Target sequence restriction (PAM)
Efficiency is low






Efficacy depends on the level of gene expression
Large genomic areas can be affected
Most modifications are not permanent
Epigenetic editing Long-term modification
Cell reprogramming
Lack of information on epigenetic marks for some targeted genes
May affect large genomic regions
Simultaneous modification of several epigenetic marks may be
necessary
as homology-mediated end joining (HMEJ) (Yao et al., 2017a)
and single homology arm donor-mediated intron-targeting
integration (SATI) (Suzuki et al., 2019). These techniques have
yielded significantly higher rates of gene insertion in post-
mitotic cells, although the mechanisms involved are not fully
understood. Other groups have suggested approaches in which
HDR repair is promoted by fusing the Cas9 nuclease to factors
involved in the regulation of NHEJ/HDR pathways. For instance,
p53-binding protein 1 (53BP1), which plays a major role in
balancing NHEJ/HDR ratio, promotes DSB repair via the NHEJ
pathway by preventing the DNA end resection required for
HDR (Bunting et al., 2010). Cas9 fused to a dominant-negative
53BP1 enhances HDR and inhibits NHEJ in a target-specific
manner, without modifying cellular DNA repair mechanisms
overall (Jayavaradhan et al., 2019). Efforts have also been made
to improve HDR by fusing Cas9 to RecA (RAD51 in eukaryotes),
which plays a key role in homologous recombination (Cai et al.,
2019; Kurihara et al., 2020), or by altering the conformational
checkpoints for Cas9 binding to DNA (Kato-Inui et al., 2018).
No product for therapeutic gene editing has yet been
approved, but the first clinical trials based on this technology have
demonstrated the safety of this approach (Schacker and Seimetz,
2019). However, as gene editing permanently modifies the DNA,
several biosafety concerns have been raised concerning the
induction of off-target DSBs and increases in genomic instability
(Mills et al., 2003). Unlike DSBs, DNA single-strand breaks
(SSBs) are common events under physiological conditions, and
are less harmful than DSBs (Caldecott, 2008). Nickases were
developed by mutating one of the catalytic sites of Cas9 (nCas9),
such that only one strand of the DNA is cut (Doudna, 2020)
(Figure 1A). Paired nickases targeting nearby sequences on
opposing strands can create specific DSBs, while decreasing the
chances of producing off-target DSBs (Dabrowska et al., 2018; Ge
and Hunter, 2019). The use of SSBs and ssDNA repair templates
to insert specific sequences has been explored as an alternative
to DSB-mediated HDR (Rees et al., 2019). Nickase variants
have improved the HDR:indel ratio, but, overall, this approach
remains less efficient than DSB-mediated recombination.
BASE EDITING
DNA base editing can be used to modify single nucleotides
without the need to introduce DSBs, reducing the risk of creating
off-target indels (Rees and Liu, 2018; Molla and Yang, 2019).
Base editing could potentially be used to correct pathogenic point
mutations, the most common type of human genetic disorders
(Landrum et al., 2016). DNA base editors have been generated
by fusing catalysis-deficient Cas9 (dCas9) or nCas9 to deaminase
enzymes, which convert specific nucleotides (Komor et al., 2016;
Nishida et al., 2016; Gaudelli et al., 2017) (Figure 2A). These tools
make use of the sgRNA/Cas-mediated R-loop structure to target
the transient ssDNA with cytosine or adenosine deaminases.
Cytosine base editors (CBEs) convert cytosine into uracil
(C→U), which has similar base-pairing properties to thymine
(T). The U is then converted to T via DNA repair mechanisms
based on base excision repair (BER) or mismatch repair (MMR),
resulting in the conversion of C·G into T·A base pairs. The first
generation of CBEs (BE1) was developed by fusing dCas9 to the
apolipoprotein B mRNA-editing enzyme, catalytic polypeptide 1
(APOBEC1) (Komor et al., 2016). This tool converted cytosine
nucleotides in the test tube, but not in eukaryotic cells. The
authors rapidly realized that the poor cytosine conversion in
cells might be due to intrinsic U:G mismatch repair mechanisms.
Uracil is one of the most common non-canonical bases in
DNA and its removal by DNA repair mechanisms is important,
to prevent mutagenesis. Uracil removal is initiated by uracil
DNA glycolase (UDG), which excises the uracil and triggers the
conversion of U:G into C:G base pairs by BER. Consequently,
the second generation of CBEs (BE2) were fused to a uracil
DNA glycosylase inhibitor (UGI), to prevent uracil base excision
repair, considerably improving cytosine editing. Attempts were
then made, in the third generation of CBEs (BE3) to favor
the incorporation of the modified nucleotide through the
use of nCas9 rather than dCas9, to induce a “nick” in the
unedited strand, thereby favoring the correction of the non-
edited nucleotides by the DNA mismatch repair machinery.
This resulted in higher cytosine conversion efficiencies, but also
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FIGURE 1 | Gene editing tools and therapeutic approaches. (A) Gene editing tools are based on TALEs, ZFs and CRISPR/Cas platforms. Site-specific TALENs and
ZFNs consist of two modules of TALEs and ZFs fused to the FokI nuclease. Both modules recognize adjacent sequences in opposite strands to promote the
dimerization of FokI and sequence cleavage in a staggered fashion. In contrast, CRISPR/Cas systems hold intrinsic nuclease activity. Cas nucleases or Cas nickases
are explored to produce either DSBs or SSBs in the targeted sequence, respectively. Alternatively, paired nickases targeting adjacent sequences in opposite strands
generate staggered DSBs. (B) Gene editing therapeutic approaches rely on the intrinsic DNA repair mechanisms NHEJ and HDR after generation of DSBs. Gene
disruption by NHEJ involves the introduction of indels after generation of DSBs at the coding region of a pathogenic gene, resulting in the formation of a premature
stop codon. Gene correction by NHEJ implicates the targeting of the non-coding region of a pathogenic gene. It includes the removal of deleterious exons by the
simultaneous cleavage in both upstream and downstream intronic regions and/or disruption of splicing regulation sites. Both gene repair and gene insertion by HDR
involve the use of donor templates containing intended sequences flanked by homology arms. In the first case, the template is targeted to the pathogenic gene and
contains the corrected sequence allowing gene restoration. In contrast, gene insertion by HDR targets safe harbor locations in the genome to introduce therapeutic
transgene expression cassettes.
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FIGURE 2 | Base editing tools and therapeutic approaches. (A) Base editors consist of Cas nickases fused to cytosine (CBEs) or adenine ssDNA deaminases
(ABEs). CBEs are fused to either AID or APOBEC1 (pink), which convert C into U, whereas ABEs are fused to an evolved TadA (TadA*) followed by a wild-type TadA
fusion (brown), which convert A into I. The consequent G:U and T:I mismatches are then corrected by the cellular DNA repair mechanisms. To favor the correction of
the non-edited nucleotides by the DNA mismatch repair machinery, the nickase introduces a “nick” in the unedited strand. The correction of the non-edited strand
results in a final conversion of C:G into T:A base pairs and A:T into G:C base pairs by CBEs and ABEs, respectively. CBEs are usually fused to the UGI to prevent the
rapid removal of uracil by BER (blue). (B) Base editing therapeutic approaches include the repair of pathogenic genes by correcting point mutations or the
inactivation of toxic genes by generating a premature stop codon.
increased the frequency of indel events. Indel formation in this
context probably results from the creation of two adjacent DNA
nicks on opposite strands (by nCas9 on the unedited strand
and by BER enzymes on the edited strand), leading to the
generation and NHEJ-mediated processing of transient DSBs.
For this reason, a fourth generation of CBEs was generated by
fusing nCas9 to two UGIs (BE4) and/or to the bacteriophage
Mu-derived Gam (BE4-GAM), which binds to DSBs and protects
them from degradation (Komor et al., 2017). The BE4 editors
underwent further improvement, based on the modification of
nuclear localization signals, codon optimization and deaminase
reconstruction (BE4max) (Koblan et al., 2018). In parallel, CBEs
were generated with an ortholog of activation-induced cytidine
deaminase A (AID) from sea lamprey (PmCDA1) rather than
APOBEC1 (Nishida et al., 2016). CDA1-nCas9-UGI had editing
rates similar to those of APOBEC1-nCas9-UGI, but achieved
through periodic decreases in incubation temperature to 25◦C,
the optimal temperature for PmCDA1. An extended toolbox of
DNA CBEs is now available. These editors differ in terms of
their Cas proteins (Cas9 or Cas12a), nuclease activity (dCas or
nCas), cytosine deaminase (APOBEC1 or CDA1), number of
UGIs, nuclear localization signals and the linker sizes between
domains (Rees and Liu, 2018; Molla and Yang, 2019).
Adenine base editors (ABEs) transform adenine into ionosine
(A→I), which is then converted to guanine (G), resulting in
the conversion of A·T into G·C base pairs (Figure 2A). ABEs
were generated based on the tRNA adenine deaminase (TadA)
of Escherichia coli (Gaudelli et al., 2017). After several rounds
of development, it was established that the fusion of nCas9
to an evolved TadA (TadA∗) followed by a wild-type TadA
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resulted in the most efficient ABE (ABE 7.10). The DNA repair
mechanisms for removing ionosine from the DNA are less
efficient than those for removing uracil, and these tools were,
therefore, able to induce high levels of adenine conversion
without the need for ionosine repair inhibitors. Consequently,
indel events were much less frequent (barely detectable) than
in untreated samples. As for BE4max, the efficiency of ABE7.10
was also increased by the development of ABEmax (Koblan
et al., 2018). The TadA∗-TadA effector domain was fused to
several Cas9 variants, recognizing different PAMs, to increase
the breadth of targeting possible for ABEs (Rees and Liu, 2018;
Molla and Yang, 2019).
Base editing is dependent on DNA mismatch repair
rather than homologous recombination. It therefore constitutes
an alternative approach to HDR-mediated gene editing for
correcting point mutations in post-mitotic cells. CBEs and ABEs
have been used to correct both LOF and GOF pathogenic point
mutations implicated in various diseases (Komor et al., 2016;
Gaudelli et al., 2017; Liang et al., 2017; Koblan et al., 2018;
Zeng et al., 2018) (Figure 2B). In vivo base editing applications
have been described for hypercholesterolemia (Chadwick et al.,
2017; Rossidis et al., 2018), hearing loss (Yeh et al., 2018,
2020), hereditary tyrosinemia type 1 (Rossidis et al., 2018),
phenylketonuria (Villiger et al., 2018), DMD (Ryu et al., 2018)
and amyotrophic lateral sclerosis (ALS) (Lim et al., 2020).
Another therapeutic strategy involves the generation of a
premature stop codon for gene inactivation, as an alternative to
NHEJ-mediated gene editing (Billon et al., 2017; Kuscu et al.,
2017) (Figure 2B).
Base editing is a promising therapeutic strategy, but it is
subject to limitations in terms of the purity of the edited products,
bystander base editing and distal off-target activity. Product
purity is defined as the ratio of intended to unintended editing
events at the targeted site. Uracil is more prone to repair by
base excision repair mechanisms, so product purity is lower for
CBEs than for ABEs. This translates into a higher rate of C
to non-T nucleotide conversion and indel events than of A to
non-G conversions and indels generated by ABEs. Bystander
base editing also lowers product purity by modifying base pairs
adjacent to the targeted nucleotide. Bystander editing of adjacent
Cs or As can be counteracted by employing base editors with
narrow editing windows, although some such editors are less
efficient. For distal off-target editing, CBEs have been shown to
generate more off-target mutations than ABEs (Lee H.K. et al.,
2018; Zuo et al., 2019). Base editors have been shown to induce
unintended modifications in both DNA and RNA. Indeed, a
recent report demonstrated substantial levels of off-target editing
in RNA, for both CBEs and ABEs (Zhou et al., 2019). Distal off-
target editing may result from non-specific Cas protein binding
to DNA and RNA or random contacts between the deaminase
domains and RNA or ssDNA during DNA replication and
transcription (Rees and Liu, 2018; Molla and Yang, 2019). Cas-
dependent off-target editing has been reduced by the use of
high-fidelity Cas variants, and other types of off-target editing
can be limited by altering the intrinsic DNA and RNA affinity of
deaminase domains.
Genome Regulation
Genome regulation offers additional therapeutic options through
the modulation of gene expression at native loci. Gene
expression is regulated by multiple factors, including both cis
and trans elements, ultimately leading to the recruitment of
RNA polymerases to promoter regions. Genome expression is
also regulated by epigenetic marks, which determine chromatin
accessibility state and comprise multiple elements, including the
three-dimensional architecture of the DNA and histone or DNA
modifications (Holtzman and Gersbach, 2018). An extensive
list of possible histone modifications, including acetylation,
methylation and phosphorylation, has been described, and all
these processes can be altered to modulate gene expression
(Holtzman and Gersbach, 2018). Epigenetic modifications,
particularly for histone tails and DNA methylation status, have
provided insight into the role of such changes in gene regulation
and their contribution to disease. For instance, cytosine
methylation (5C-methylcytosine) at CpG dinucleotides is usually
enriched in silenced promoters (Weber et al., 2007; Kundaje
et al., 2015) and has been implicated in genomic imprinting
(Laan et al., 1999), whereas H3K9 acetylation is associated
with active promoters (Ernst et al., 2011). For the alteration or
restoration of gene expression profiles, ZFs, TALEs, and dCas
proteins have been fused to scaffold transcriptional modulators or
epigenetic modifiers (Figure 3A). Genome regulation strategies
can be used to upregulate or repress gene expression by two
different approaches: (1) transcriptional modulation through the
recruitment of transcription factors and chromatin remodelers
and (2) epigenome editing through the direct modification of
epigenetic marks.
Transcriptional activation has been achieved through the
tethering of ZFs, TALEs, and dCas9 to several copies of
herpes simplex virus protein 16 (VP16), the transactivating
domain of the NF-kB p65 subunit (p65), heat shock factor
1 (HSF1) and Epstein–Barr virus R transactivator (RTA)
(Figure 3B). The targeting of multiple copies of transactivating
domains to promoter regions was rapidly shown to have a
synergistic activation effect. This led to the development of dCas-
based second-generation activators, which can target multiple
transactivating domains to a single locus. Chavez and coworkers
evaluated the potency of several dCas9 activators in different
cell lines and showed that the synergistic activator mediator
(SAM) (Konermann et al., 2015), SUperNova Tagging (SunTag)
(Tanenbaum et al., 2014) and the tripartite VP64-p65-RTA (VPR)
(Chavez et al., 2015) systems were the most efficient at inducing
gene activation (Chavez et al., 2016). These systems have been
adapted to activate genes in vivo (Chew et al., 2016; Liao et al.,
2017; Moreno et al., 2018; Zhou et al., 2018; Breinig et al.,
2019; Savell et al., 2019; Zhan et al., 2019). Gene expression
profiles can also be altered to reprogram cells to differentiate
into particular cell types. Liao and coworkers reprogrammed
hepatic cells into pancreatic-like beta cells, by activating the
Pdx1 (Liao et al., 2017). They also improved DMD symptoms
by activating the Utrn gene. Savell and coworkers demonstrated
robust Fosb activation in several regions of the brain in vivo
(Savell et al., 2019). Similarly, Zhou et al. demonstrated the
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in vivo genetic reprogramming of neurons in mouse brain
by simultaneously activating the expression of Ascl1, Neurog2,
and Neurod1 (Zhou et al., 2018). Breinig and coworkers recently
altered the sgRNA length of a Cas12a-VPR variant to induce
either gene activation or knockout in vivo (Breinig et al., 2019).
This work has added an additional degree of complexity to these
systems, allowing not only the targeting of multiple genes, but
also a larger range of modifications. Artificial transcriptional
repressors have also been generated by fusing the Kruppel-
associated box protein (KRAB) domain to the DNA-binding
platforms (Bailus et al., 2016; Zeitler et al., 2019) (Figure 3B).
KRAB is a scaffold protein involved in recruiting KAP1/TIF1β
corepressor complexes, which in turn recruit DNA methylases
or histone modifier factors (Kim et al., 1996; Ying et al., 2015).
The effects of KRAB on gene repression can be permanent or
reversible, depending on developmental stage (Ying et al., 2015).
Unlike the recruitment of activating or repressing
complexes/factors, epigenetic editing can modify epigenetic
marks by targeting specific enzymes. Epigenetic activation
has been achieved through site-specific DNA methylation by
the DNA demethylase 10–11 translocation methylcytosine
dioxygenase 1 (TET1) (Maeder et al., 2013; Choudhury et al.,
2016a; Liu et al., 2016; Xu et al., 2016) or with enzymes promoting
activating histone signatures, such as the histone acetylase core
subunit p300 (Hilton et al., 2015) and histone methyltransferases
(Cano-Rodriguez et al., 2016) (Figures 3C,D). For instance,
Liu and coworkers described the in vivo demethylation of a
methylation-sensitive Snrpn-GFP cassette in transgenic mice
(Liu et al., 2016). Heterozygous mice carrying a paternal copy
of the transgene do not express GFP, due to the methylated
status of this copy of the gene. The authors reported the
targeted active demethylation of the transgenic cassette and a
70% activation of GFP expression after lentiviral injections
of dCas9-Tet1 into the brain. Rather than active DNA
demethylation, Hilton et al. demonstrated that the fusion
of p300 to the three DNA-binding platforms activated the
expression of multiple endogenous genes (ilrn1, oct4, and
myod1) through histone acetylation (Hilton et al., 2015). Finally,
epigenetic repression has been achieved through direct DNA
methylation (Bernstein et al., 2015), histone deacetylation
(Kwon et al., 2017), and histone demethylation (Kearns et al.,
2015) (Figures 3C,D).
GENOME EDITING FOR CNS
DISORDERS
Alzheimer’s Disease
Alzheimer’s disease (AD) is the main cause of dementia, affecting
millions of people worldwide (Winblad et al., 2016; Dos Santos
Picanco et al., 2018). One of the hallmarks of AD is the presence
of scattered extracellular senile plaques, due to the accumulation
of amyloid-β (Aβ) in the brain. Aβ is a secondary metabolite
generated by the processing of amyloid precursor protein (APP)
by β-secretase 1 (BACE1). Alternatively, APP may be processed
via a non-amyloidogenic pathway involving α-secretases,
leading to the generation of neuroprotective products
(Richter et al., 2018). In a study of the treatment of a familial
form of AD caused by the Swedish mutation of APP (APPsw),
CRISPR-mediated NHEJ was used to inactivate the mutant
APP (György et al., 2018). This can be achieved by designing
sgRNAs targeting single nucleotide polymorphisms (SNPs) in
the target sequence of the sgRNA (mismatch-based selectivity)
or in the PAM (PAM-based selectivity). György and coworkers
detected 1.3% indels in the APPsw allele after the hippocampal
injection of a mismatch-based selective CRISPR/Cas9 system
split into two AAV9 vectors (because of the limited capacity
of AAV vectors of ∼4.8 kb) in Tg2576 mice (György et al.,
2018). By contrast, Sun and coworkers used a non-allele selective
CRISPR-mediated NHEJ strategy to push APP processing toward
the non-amyloidogenic pathway (Sun et al., 2019). Based on
evidence suggesting that deletion of the C-terminus of APP can
mitigate Aβ generation (Koo and Squazzo, 1994) and reduce
APP interactions with the BACE-1 enzyme (Das et al., 2016),
the authors used CRISPR to generate C-terminally truncated
APP, thereby circumventing the amyloidogenic processing of
APP (Sun et al., 2019). In this study, APP truncation in WT
and heterozygous APP-London human iPSC-derived neurons
increased the production of the neuroprotective sAPPα and
reduced the secretion of Aβ40/42 and the sAPPβ fragment. For
in vivo studies in adult mice, the CRISPR-APP system was split
into two AAV9 vectors and delivered to the dentate gyrus of WT
mouse brains. The injection of CRISPR-APP led to a halving
of full-length APP levels relative to both controls not receiving
injections and controls receiving control vector injections. No
additional in vivo tests were performed to evaluate treatment
efficacy in the context of AD (György et al., 2018; Sun et al., 2019),
but these therapeutic strategies targeting the C-terminal part of
APP are of interest because the aim was to attenuate pathological
properties (Aβ generation) while potentially maintaining other
physiological functions of APP. Another approach, developed by
Park and coworkers, uses CRISPR-Cas9-loaded nanocomplexes
targeting BACE1 in the 5XFAD and APP transgenic mouse
models to reduce the generation of Aβ and improve AD
symptoms (Park et al., 2019). Four weeks after CRISPR injection
into the CA3 hippocampal region of 5XFAD mice, 45% of
target sequences contained indels, and a 34% decrease in Bace1
expression was observed, revealing this method to be more
efficient than the use of chemical BACE1 inhibitors. They
also observed a decrease in Aβ plaque accumulation by a
factor of more than two, together with a significant rescue of
associative learning (fear conditioning test) and spatial working
memory (Morris water maze) in the treated 5XFAD mice. These
molecular and behavioral improvements were maintained for up
to 12 weeks. Off-target evaluation by whole-genome sequencing
(WGS), whole-exome sequencing (WES), Digenome-sequencing
(Digenome-seq) and deep sequencing identified a few off-target
mutations and small-scale chromosomal rearrangements.
Bustos and coworkers investigated the potential of epigenome
editing for AD by targeting the dlg4 gene, encoding the PSD95
protein (Bustos et al., 2017). PSD95 is a scaffolding protein
present at the excitatory post-synaptic density, and is involved
in the regulation and organization of post-synaptic synapses
(Elias and Nicoll, 2007). Abnormal PSD95 expression has been
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FIGURE 3 | Transcriptional regulators, epigenetic modifiers, and therapeutic approaches. (A) Gene expression regulation tools are generated by fusing TALEs, ZFs
or dCas proteins to scaffold transcriptional modulators or to epigenetic modifiers (B) Therapeutic approaches by transcriptional regulation. Transcriptional activation
or repression is explored to upregulate therapeutic genes or to downregulate deleterious genes, respectively. Transcriptional activators are targeted at the promoter
region whereas transcriptional repressors are usually targeted downstream to the transcription starting site to further block the RNA polymerase activity.
(C) Therapeutic approaches through histone modification. Histone (de)acetylases and (de)methylases are the most common employed enzymes to modify histone
marks and the epigenetic activation or inhibition effect of such modifications is frequently context-specific. (D) Therapeutic approaches by editing the DNA
methylation state. Epigenetic editors based on DNA demethylases are used to activate gene expression whereas the ones based on DNA methylases result in gene
expression inhibition.
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described not only in AD, but also in other neurological
disorders, such as Huntington’s disease (HD) and schizophrenia.
The authors developed and validated in vitro several ZF-based
epigenome modifiers targeting the proximal promoter region of
dlg4/PSD95 for the activation or repression of PSD95 expression
(Bustos et al., 2017). They demonstrated that alterations in
expression were specifically associated with histone modifications
rather than other changes, such as CpG methylation in DNA.
The fusion of zinc fingers to the histone methyltransferase
G9a (PSD95-6ZF-G9a) induced gene repression associated with
an increase in the di- and tri-methylation of H3K9, whereas
PSD95-6ZF-VP64 gene activation was coupled to H3 activation,
probably through the recruitment of histone acetylases by
the VP64 domain. PSD95-6ZF-VP64 was also shown to have
neuroprotective effects. AβPPswe/PS-1 mice receiving AAV-
PSD95-6ZF-VP64 injections into the hippocampus had higher
levels of PSD95 expression and displayed a rescue of memory and
spatial learning performances to normal aged-matched levels.
Parkinson’s Disease
Parkinson’s disease (PD) is the second most common
neurodegenerative disorder, affecting 2–3% of people under
the age of 65 years (Poewe et al., 2017). PD patients display
motor movement dysfunction, but also cognitive impairment,
depression and dementia. At the cellular and molecular levels,
PD is characterized by a striatal dopamine deficiency due to
progressive neuronal loss in the substantia nigra, and by the
formation of intracellular aggregates containing α-synuclein.
Dopamine loss and basal ganglia circuitry disruption are well-
defined features in PD, but this disease is extremely complex and
driven by diverse molecular and neurophysiological mechanisms.
Several gene-based therapies for PD have been proposed,
including the targeting of α-synuclein, cellular oxidation and
the autophagy-lysosomal pathway (Poewe et al., 2017). Genome
editing for PD has mostly been used for disease modeling in vitro
(Safari et al., 2019). For instance, Kantor and coworkers induced
the hypermethylation of CpG islands in SNCA intron 1 in
iPS-derived dopaminergic progenitor neurons, through lentiviral
transduction with a dCas9-DNMT3A system (Kantor et al.,
2018). They observed a ∼ 25% decrease in α-synuclein protein
levels and the rescue of mitochondrial-associated superoxide
production and cell viability. They observed no overall change in
the methylation status of the treated cells, identifying the dCas9-
DNMT3A-mediated targeting of SNCA as a promising approach
for PD treatment. Another potential therapeutic target is glial cell
line-derived neurotrophic factor (GDNF), which has been shown
to have neuroprotective effects and to improve Parkinsonian
symptoms (Kordower et al., 2000; Tenenbaum and Humbert-
Claude, 2017). Laganiere and colleagues used a ZF-p65 fusion to
upregulate the expression of endogenous GDNF in a 6-OHDA
rat model of Parkinson’s disease (Laganiere et al., 2010). They
observed an increase in the number of TH-positive fibers in
both the medial forebrain bundle and the substantia nigra after
7 weeks of AAV2-rGDNF-ZFP infusion (Laganiere et al., 2010).
The rGDNF-ZFP-treated group performed better in the corridor
test, the cylinder test and the drug-induced rotational test than
the GFP-treated control. This study yielded promising results,
but a clinical trial based on the direct infusion of GDNF into the
putamen resulted in no significant improvement of Parkinson’s
disease symptoms (Lang et al., 2006; Whone et al., 2019), raising
questions about therapeutic efficacy of GDNF.
Huntington’s Disease
Huntington’s disease (HD) is a neurodegenerative disorder
caused by an inherited dominant CAG trinucleotide expansion
mutation on the HTT gene. In vivo genome editing strategies for
HD have explored NHEJ-mediated gene inactivation (Merienne
et al., 2017; Monteys et al., 2017; Yang et al., 2017) and the
transcriptional repression of HTT (Zeitler et al., 2019). Yang
et al. used two separate AAVs expressing SpCas9 and two
sgRNAs targeting the flanking regions of the CAG repeat in
a non–allele-specific manner in the HD140Q-KI mouse model
(Yang et al., 2017). The injection of neuron-specific AAV-
Cas9-HTT resulted in the efficient transduction of medium
spiny neurons, significantly decreasing the accumulation of both
mutant (mHTT) and WT HTT in the striatum of 9-month-old
homozygous and heterozygous HD140Q-KI mice. The treated
heterozygous mice performed better in the rotarod, beam and
grip strength tests. Although no deleterious effects of depleting
both mutant HTT copies from homozygous HD140Q-KI mice
were detected (Yang et al., 2017), it still remains a matter of
debate whether disruption of the normal physiological functions
of WT HTT lead to harmful effects at adult stages (Liu and
Zeitlin, 2017). With this in mind, Monteys and coworkers
designed a PAM-based strategy targeting a SNP for specific
inactivation of the mutant HTT allele (Monteys et al., 2017).
They demonstrated the allele selectivity of the chosen sgRNAs
in vitro in fibroblasts from human HD patients and showed
efficient HTT exon-1-targeted deletion following the injection
of allele-selective AAV1 CRISPR-HTT into BACHD transgenic
mice. This treatment halved the levels of human mHTT mRNA
in the striatum. However, it should be noted that heterozygous
BACHD transgenic mice have about five tandem copies of
the human mHTT gene and two copies of the endogenous
mouse WT gene (Gray et al., 2008). In these studies, the
spCas9 was constitutively expressed. The stable and permanent
expression of nucleases eventually leads to higher levels of
on-targeting editing, but it also increases the occurrence of
off-target events and immunogenic responses. We have tried
to overcome this problem by developing the self-inactivating
KamiCas9 system, for transient Cas9 expression (Merienne
et al., 2017). This system is based on a lentiviral vector with
a larger cloning capacity than AAV. It is composed of the
Cas9 nuclease, a sgRNA targeting HTT and a second sgRNA
targeting the translation start site of the Cas9 nuclease. High
on-target efficiency and inactivation of the Cas9 nuclease over
time are ensured by the use of a strong PolIII promoter (H1) to
drive the sgHTT and a weak PolIII promoter (7sk) to drive the
sgCas9. We demonstrated high levels of exogenous hHTT-82Q
(20–35%) and Cas9 (∼40%) editing following the injection of
LV-KamiCas9 and hHTT-82Q into mouse striatum. Western blot
analysis of striatal samples from mice receiving LV-KamiCas9
injections revealed an almost-complete absence of the Cas9
protein after 2 months.
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Garriga-Canut et al. (2012) attempted to design a CAG
copy number-dependent ZF-based transcription repressor
exclusively targeting the mHTT allele. This first tool established
the proof-of-principle for HTT repression in vivo, decreasing
mHTT mRNA levels by about 30% in the brains of R2/6
mice receiving AAV1-ZF-Kox1 injections. Despite the
achievement of selective repression in vivo, the mutant
allele in R6/2 mice contains 115–160 repeats, a number
not consistent with the degree of CAG expansion in most
HD patients. Zeitler and coworkers recently generated a
second-generation ZF-KRAB that preferentially recognizes
pathogenic CAG repeats, and demonstrated highly significant
mHTT suppression with wild-type allele preservation in
patient derived-iPSCs (Zeitler et al., 2019). They observed
beneficial behavioral effects in R6/2 mice for 7 weeks after the
intrastriatal injection of AAV-ZF-KRAB, and demonstrated
the absence of inflammation or adverse effects of long-term
expression in mouse brain.
Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis is a neurodegenerative disease
caused by the progressive neurodegeneration of both upper and
lower motor neurons (Rowland and Shneider, 2001). Muscle
atrophy begins in adult patients with ALS and progresses to
total paralysis and, eventually, death. Approximately 2% of ALS
cases result from a dominant mutation of the SOD1 gene. Gaj
et al. (2017) mitigated ALS symptoms and improved the survival
of a mouse model of ALS, G93A-SOD1 mice, containing 25
copies of the human mutant SOD1, by disrupting the human
SOD1 gene with the Staphylococcus aureus Cas9 (SaCas9).
The CRISPR system was packaged into a single AAV9 variant
(double-tyrosine mutant) shown to enhance gene transfer to
the CNS (Petrs-Silva et al., 2009; Dalkara et al., 2012). The
authors demonstrated efficient neuronal transduction of the
ventral horn of the spinal cord, with up to 74% of motor
neurons expressing the nuclease, after systemic injections in
neonatal transgenic mice (Gaj et al., 2017). Western blot analysis
revealed a 2.5- to 3-fold decrease in mutant SOD1 protein
levels, but sequencing data showed that only a small fraction
of the total human SOD1 transgenes had been edited (0.2–
0.4%). This discrepancy may reflect the large numbers of glial
cells in the gray matter of the spinal cord, which were not
efficiently transduced, or differences in SOD1 expression in
transduced and non-transduced regions of the spinal cord.
Regardless of this divergence, the onset of disease in animals
treated with SaCas9-SOD1 was delayed by 33 days, and survival
was 28–30 days longer than in the control. In age-matched
mice, the editing of SOD1 improved rotarod performance,
prevented weight loss and reduced muscular atrophy. The
treatment was unable to slow the progression of the disease
after its onset, but end-stage tissue analysis in SaCas9-SOD1-
treated mice revealed the presence of ∼50% more motor
neurons. SOD1 inclusion bodies were observed in astrocytes,
suggesting that glial cell targeting might be required to slow
the progression of the disease, since these cells have been
shown to play a role in disease progression (Boillée et al., 2006;
Yamanaka et al., 2008).
Angelman Syndrome
Angelman syndrome is a neurological disorder caused by a
genetic UBE3A deficiency resulting in intellectual disability,
ataxia and seizures (Laan et al., 1999). The paternal Ube3a allele
is specifically silenced by a brain-specific antisense transcript
(Ube3a-ATS). LOF mutations in the maternal allele therefore
lead to UBE3A deficiency. Bailus and coworkers developed
a ZF-KRAB repressor targeting the transcription start site of
Ube3a-ATS (Snurf/Snrpn promoter), to overcome the paternal
imprinting of the Ube3a gene (Bailus et al., 2016). The systemic
injection of TAT-S1-linked UBE3a-6ZF-KRAB repressor partially
rescued Ube3a expression levels in the hippocampus and
cerebellum of a mouse model of Angelman syndrome. However,
this therapeutic approach may require multiple treatments,
because the repressor function of the KRAB domain has been
shown to be transient (Gilbert et al., 2014; Ying et al., 2015).
MECP2 Duplication Syndrome
MECP2 encodes a nuclear protein involved in the transcriptional
and post-transcriptional regulation of many genes (Cheng and
Qiu, 2014). Duplication or triplication of Xq28 leads to MECP2
GOF mutations mostly affecting boys (Ramocki et al., 2009).
This syndrome is characterized by intellectual disability, poor
speech development, motor dysfunction and anxiety. Yu and
coworkers reported that the normalization of MeCP2 levels in
the medial prefrontal cortex of adult MECP2 transgenic mice
through CRISPR/Cas9-mediated NHEJ can reverse the social
recognition deficit (Yu et al., 2020). The CRISPR system was
packaged into two AAV particles (SpCas9+ sgRNA), which were
stereotaxically injected into the mouse brain. Immunostaining
and western blotting 6 weeks after treatment showed that MeCP2
protein levels had almost halved. Despite improvements in social
recognition behavior, the treatment had no effect on locomotor
activity, or heightened anxiety-like behaviors, suggesting that
different brain areas or neural circuits may contribute to the
diverse aspects of the syndrome.
Fragile X Syndrome
Fragile X syndrome (FXS) is the most common single-gene
form of autism spectrum disorders (ASDs), for which there
is currently no effective treatment (Kaplan and McCracken,
2012). It is caused by a trinucleotide CGG repeat expansion
in the 5′ UTR of the fragile X mental retardation 1 (FMR1)
gene, encoding the fragile X mental retardation protein (FMRP)
(Dölen and Bear, 2008; Persico and Napolioni, 2013). This
mutation inactivates the gene, due to hypermethylation of the
expanded repeats and heterochromatin formation. Excessive
mGluR5 signaling has been observed not only in FXS, but also in
other ASDs (Silverman et al., 2012). Lee and coworkers explored
the CRISPR-mediated disruption of metabotropic glutamate
receptor 5 (mGluR5) as a mean of counteracting FXS by
delivering RNPs SpCas9 or Cas12a targeting the mGluR5 to
the striatum of Fmr1-knockout mice (a mouse model of FXS)
(Lee B. et al., 2018). The editing tool was delivered with CRISPR-
gold technology, which combines gold nanoparticles conjugated
with oligonucleotides and the endosomal disruptive polymer
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PAsp(DET), for the transfer of RNPs into cells by endocytosis
(Lee et al., 2017). The indel frequency was 14.6%, and a 40–50%
decrease in mGluR5 mRNA and protein levels was observed.
In addition, behavioral analysis revealed that mGluR5-CRISPR-
Gold rescued the excessive digging and exaggerated repetitive
jumping behaviors of treated mice.
Traumatic CNS Injury
Traumatic CNS injuries and stroke are very common causes
of disability, and the treatments currently available are very
limited. CNS trauma involves an initial mechanical injury, which
is followed by a cascade of molecular and cellular phenomena,
ultimately leading to neuronal death by apoptosis. Genome
editing therapy strategies have focused on VEGF, which is a
neuroprotective factor that favors endothelial cell proliferation
and blood vessel formation (Shweiki et al., 1992). These studies
used engineered ZFs targeting the proximal promoter of VEGF
fused to the transactivating domain of the NF-kB p65 subunit.
Michael Fehlings’s laboratory has demonstrated an increase in
the number of blood vessels and angiogenesis, a decrease in
neurodegeneration and an improvement of behavioral outcomes
in a rat model of SCI following the intraspinal microinjection
of AdV-ZFP-VEGF and AAV2-ZFP-VEGF activators (Liu et al.,
2010). The timing of treatment for traumatic damage is an
important parameter for clinical application. Beneficial effects
have been shown following the administration of AdV-ZFP-
VEGF 24 h after injury (Figley et al., 2014). In addition,
Siddiq et al. (2012) used the unilateral fluid percussion injury
model in rats to demonstrate the neuroprotective and angiogenic
effects of ZFP-VEGF delivery to the cortex or hippocampus by
intracerebral injection. Treatment did not improve performance
in the Morris water maze or balance beam latency experiments
relative to control, but the treated group performed significantly
better than controls in the rotarod test.
GM2-Gangliosidoses
GM2-gangliosidoses are autosomal recessive disorders caused
by the deficiency of a lysosomal enzyme, β-hexosaminidase,
resulting in the accumulation of GM2 gangliosides. Biallelic
LOF mutations of the Hex α-subunit (HEXA) or Hex β-subunit
(HEXB) genes lead to Tay-Sachs disease and Sandhoff disease,
respectively. Ou and coworkers recently used a cross-correction
strategy based on liver-targeted HDR-mediated CRISPR editing
to restore the function of β-hexosaminidase in the brain, in a
Sandhoff mouse model (Ou et al., 2020). They injected a dual
AAV system consisting of AAV8-SaCas9 and AAV8-HEXM-
sgRNA targeting the albumin safe harbor locus into neonatal
Sandhoff mice, to introduce, via HDR, the coding sequence of a
modified human Hex µ subunit (HEXM) able to process GM2
gangliosides (Karumuthil-Melethil et al., 2016). Four months
after the systemic delivery of this sequence, levels of MUGS
and MUG activity in the brain were significantly higher than
those in untreated Sandhoff mice. Mice receiving the AAV8-
HEXM-sgRNA alone displayed no such increase in MUGS and
MUG activities, indicating an absence of HEXM expression from
the episomal donor template vector. In addition, treated mice
performed better in the rotarod test and one in three mice
had lower levels of neuronal lysosomal accumulation, indicating
that hepatocyte editing can lead to neurological improvements.
Indeed, the HEXM variant has been reported to improve
gangliosidosis in both the Sandhoff and Tay-Sachs models
(Karumuthil-Melethil et al., 2016; Osmon et al., 2016), suggesting
that this strategy may provide protection against both disorders.
Hearing Loss Disorders (DFNA36 and
DFNB7/11)
About 20% of the 100 or so alleles associated with deafness
result from GOF mutations (Müller and Barr-Gillespie, 2015).
DFNA36 is a progressive hearing loss disease caused by dominant
mutations of the tmc1 gene, leading to the neurodegeneration
of sensory hair cells. This disease is of particular interest due
to the existence of an orthologous mouse mutation, Beethoven
(Bth), which also causes hearing loss in mice (Zhao et al., 2014).
Two recent reports described the use in vivo of allele-specific
CRISPR-mediated NHEJ as a therapeutic strategy for DFNA36
(Gao et al., 2018; György et al., 2019). Gao and coworkers
used SpCas9 together with a sgRNA matching the mutant allele,
but not the WT allele, to knockout the mutant allele (Gao
et al., 2018). They delivered RNP complexes bound to cationic
lipids and, even though the targeting of the mutant allele was
highly selective (96% of mutant/WT), the frequency of indels
was low (1.8%). Nevertheless, the treatment was sufficiently
effective to promote hair cell survival, particularly for inner
hair cells (IHCs), and to improve cochlear function significantly
between the frequencies of 8 and 23 kHz (Gao et al., 2018).
However, at 8 weeks, an analysis of cochlear function in treated
Tmc1Bth/ + mice revealed less evident improvements relative
to the control, suggesting that higher levels of mutant gene
inactivation might be required to stop neurodegeneration, or that
the small proportion of WT alleles inactivated might neutralize
the benefits of mutant knockout over time. This strategy resulted
in allele-specific editing, but PAM-based strategies are generally
more selective, as demonstrated by György and coworkers
(György et al., 2019). They used the SaCas9-KKH variant to
edit the mutant allele in a PAM selective manner (György et al.,
2019). The SaCas9-KKH/sgRNA treatment via AAV-Anc80L65
was more selective that the treatment used in the previous study,
with no detectable indels in the WT allele and a frequency of
2.2% indels for the mutant allele. At the age of 6 months, SaCas9-
KKH/sgRNA-treated mice had significantly higher survival rates
for both inner hairy cells and outer hair cells (OHCs), with
normal hair bundle morphology in all cochlea, except for the
OHCs in the basal region, which were absent. The authors
also demonstrated the stable maintenance of low thresholds
of auditory brainstem responses for up to 40 weeks. Finally,
GUIDESeq analysis detected no genome-wide off-target events
in Tmc1WT/WT fibroblasts, further highlighting the potential
interest of AAV-SaCas9-KKH-sgTmc as a therapeutic strategy for
DFNA36 hearing loss.
DNFA36 results from GOF mutations of the tmc1 gene,
whereas LOF mutations in both tmc1 alleles result in the
autosomal recessive congenital DFNB7/B11 hearing loss
disorder. Gene disruption approaches are not suitable for
the treatment of DFNB7/B11. Yeh and coworkers explored
























TABLE 2 | Preclinical studies of genome editing for CNS pathologies.
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the use of a base editing strategy to correct the tmc1 alleles
in Tmc1Y182C/Y182C mice (Yeh et al., 2020). They reported
2.3% base editing in a bulk organ of Corti at P14 after the
injection of a dual AAV system encoding AID-BE into the inner
ear at P1. Tmc1 is expressed only in hair cells. The authors
therefore analyzed base editing at the RNA level, to improve the
quantification of editing in these cells. They observed ∼ 50%
editing in the cDNA, but these results must be interpreted with
caution because they may not reflect the editing at the DNA level.
The treatment of mice resulted in the preservation of hair bundle
morphology and a restoration of the mechanotransduction
current in the sensory hair cells. There were 46% more hair cells
in the treated mice 4 weeks after injection, with a progressive
decrease in cell numbers thereafter, until 6 weeks. The decrease
in cell survival was followed by a decline in hearing function,
suggesting that more efficient base editing is required to prevent
the degeneration of hair cells over time.
Retinitis Pigmentosa
Retinitis pigmentosa (RP) is an inherited disorder and the
most common cause of progressive vision loss (Kalloniatis and
Fletcher, 2004). It is defined by an initial progressive loss of rod
photoreceptors, followed by cone photoreceptor degeneration.
One form of RP results from a biallelic LOF mutation in the
PDE6B gene, introducing a premature stop codon. Cai et al.
used HDR-mediated CRISPR editing to correct the mutation
(Cai et al., 2019). In this study, the authors developed an
improved CRISPR system for HDR (Cas9/RecA) consisting of
a sgRNA with MS2 aptamers for the recruitment of MS2-RecA
fusion proteins to the target site to promote recombination
between the cleavage site and a ssDNA donor template. The
potential of this tool to repair the PDE6B gene was evaluated
by electroporating the retinas of WT and rd1 mice with four
plasmids (SpCas9+ sgRNA-MS2apt+MS2-RecA+ ssTemplate)
at P0. A 2% restoration of PDE6B WT protein levels was observed
in Cas9/RecA-treated mice, whereas no wild-type PDE6B
protein was detected in Cas9-treated mice (SpCas9 + sgRNA-
MS2apt + ssTemplate), indicating that Cas9/RecA enhances
HDR efficiency. Cas/RecA treatment at P0 rescued both rod
and cone photoreceptors, but the degree of rescue was 1.8-
and 1.6-fold lower, respectively, when mice were treated at P3,
suggesting that the loss of photoreceptor proliferation had a
negative effect on HDR-mediated correction. In addition, an
analysis of visual function and pupillary light reflexes revealed
that Cas9/RecA partially rescued the pupillary light reflexes of rd1
mice, demonstrating beneficial effects of treatment.
Leber Congenital Amaurosis Type 10
Leber congenital amaurosis type 10 (LCA10) is an autosomal
recessive condition causing early blindness in infancy (Stone,
2007; Stone et al., 2017). It is defined by LOF mutations of
both CEP290 alleles. The IVS26 point mutation creating a new
splice donor site is the most frequent defect. It alters transcript
splicing and generates a premature stop codon in the processed
mRNA. Maeder and coworkers recently reported an exhaustive
drug dosing study of the use of AAV5-SaCas9-mediated NHEJ
to correct the IVS26-driven aberrant CEP290 splicing in
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retina photoreceptor cells (EDIT-101) (Maeder et al., 2019). The
proposed strategy induced a cleavage on either side of the
mutation, with a pair of sgRNAs used to delete or invert the
fragment containing the IVS26 mutation. The authors evaluated
the kinetics and dose response of the editing system in the
retina of CEP290 IVS26-KI mice and cynomolgus monkeys, in
which maximum editing rates of 21.4 and 27.9%, respectively,
were obtained. They also demonstrated ocular tolerability in
all animals, except those without immunosuppression regimens,
which displayed mild inflammation. This report resulted in
the first approved preclinical study of CNS genome editing
for clinical trial continuation in humans (NCT03872479).
The cep290 cDNA is ∼7.5 kb long, a size well-beyond the
capacity of the AAV vectors used for gene replacement. This
approach demonstrates the therapeutic potential of gene repair
for counteracting CNS disorders without the need to provide
exogenous WT transgenes.
FUTURE PERSPECTIVES IN GENOME
EDITING FOR CNS DISORDERS
The field of genome editing is rapidly evolving and there is now a
broad genome editing toolbox that can be used for therapeutic
purposes. The efficacy of genome-editing therapies for CNS
disorders will depend on the choice of the most appropriate
tool to tackle the genetic defect and the type and magnitude of
editing required for therapeutic benefit. In addition, the types of
cells and CNS areas to be edited should be taken into account.
Local genome editing may be sufficient for some disorders, but
others may require the editing of large areas. For instance, eye
disorders are more accessible due to their peripheral localization
and the relatively small area targeted, whereas the neuronal
damage in AD covers large brain regions (Dos Santos Picanco
et al., 2018). It is, therefore, crucial to select the most suitable
delivery vehicle according to the editing tool used and the target
area. The delivery of genome editing tools is probably one of
the major limiting steps when targeting the CNS. Viral-mediated
delivery by lentiviral (LV) and AAV vectors is the approach most
frequently used to date, due to their high efficiency to transfer
genetic material into cells (Spencer et al., 2020). LV have a large
loading capacity but integrate into the host genome, potentially
leading to insertional mutagenesis, whereas AAVs mostly persist
as an extrachromosomal episome but have a limited cloning
capacity. The generation of non-integrative lentiviral vectors
(Shaw et al., 2017) and the use of dual AAV delivery systems
(Yang et al., 2017; György et al., 2018; Sun et al., 2019) are two
alternatives for overcoming these problems. Viral tropism has
also been used to target specific cell types and to increase the
area of transduction by either viral neuronal retrograde transport
or through the use of serotypes with wide diffusion properties
(Lykken et al., 2018). Local intraparenchymal injections are the
most common delivery method for circumventing the BBB,
but some AAV serotypes have been shown to cross the BBB
after systemic delivery (Choudhury et al., 2016b; Chan et al.,
2017; Hudry et al., 2018). Non-viral vehicles are generally less
efficient than viral vectors, but the development of non-viral
delivery methods for the CNS is an intense field of research and
may open up new possibilities for treatment in the near future
(Wang and Huang, 2019).
The immunogenicity induced by genome editing tools is
another topic of concern due to potential inflammatory responses
(Shim et al., 2017). For instance, the injection of non-host-
matched, but not host-matched ZFNs, into the mouse brain
resulted in microglial activation and mild neuronal death
(Agustín-Pavón et al., 2016). Similarly, CRISPR/Cas9 was shown
to induce the both cellular and humoral immune responses
in mouse models (Mehta and Merkel, 2020). Immunogenicity
can be minimized by transient expression. Transient expression
strategies have been mainly developed for CRISPR/Cas-based
tools either through the delivery of RNPs or ON/OFF expression
systems. These include self-inactivation systems (Merienne et al.,
2017; Li et al., 2018) and the use of drug inducible promoters,
such as the doxycycline (dox)-induced Tet or the Tamoxifen-
dependent Cre promoters (Zhang et al., 2019). However, the
optimization of self-inactivation kinetics and the requirement
of additional molecules to regulate promoters will delay the
translation of these strategies to the clinic. Additionally, these
strategies will be only suitable if the transient expression of the
tool is sufficient to achieve therapeutic benefit.
Transient systems have also been developed to decrease off-
target modifications. We showed that off-target events were
reduced with the KamiCas9 compared to the constitutively
expressed Cas9 (Merienne et al., 2017). Other groups have
engineered Cas9 binding properties to increase specificity and
attenuate off-target editing (Cebrian-Serrano and Davies, 2017;
Hu et al., 2018; Kocak et al., 2019). Similarly, base editors and
transcriptional/epigenetic editors also present off-target effects.
For instance, base editors induce off-targets at both DNA and
RNA levels (Zhou et al., 2019) whereas the KRAB domain has
been shown to affect long chromosomal regions (Groner et al.,
2010). There is thus the need for the development of highly
specific editing systems to minimize safety concerns and ease
their clinical application.
Finally, on-target events should also be properly characterized.
Gene editing generates chimeric outcomes by introducing
heterogeneous indels. For instance, the CRISPR/Cas9 targeting of
the HTT translation starting site followed by NHEJ may generate
truncated proteins with polyserine or polyalanine expansions,
which have been shown to play a role in the disease (Berger et al.,
2006). Furthermore, when attempting HDR-based strategies,
NHEJ and HDR are competing pathways, and DSBs may be
repaired by both mechanisms in the presence of a repair template
(Weisheit et al., 2020). Likewise, bystander editing during base
editing may give rise to unintended edited products which might
even intensify the pathological processes. In addition, genome
editing events may also be neutralized by intrinsic compensatory
mechanisms, reducing the therapeutic effects (Smits et al., 2019).
In this review, we have focused on examples of in vivo
therapies for CNS disorders (Table 2), but extensive efforts
have been conducted to improve genome editing strategies. Two
examples are the recently proposed prime editing approach
(Anzalone et al., 2019) and the usage of transposases for
genome engineering, which may become alternative options
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for the treatment of CNS disorders in the near future
(Anzalone et al., 2020; Doudna, 2020). In summary, it is
acknowledged that multiple aspects require further improvement
to establish CNS genome-editing therapies but the field is
advancing at an astonishing pace, bringing us closer every day
to possible clinical applications.
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